ABSTRACT Background Energy‐based treatments for atrophic acne scars (AAS) in darker skin phototypes must balance efficacy with pigmentary safety. While the nonablative 675‐nm laser has shown promise with minimal risk of adverse effects, prospective data in Asian populations remain limited. This study evaluated the efficacy, tolerability, and safety of a 675‐nm laser for AAS in Fitzpatrick skin types (FSTs) III–IV. Methods Sixteen adults with AAS underwent 3 monthly sessions using sequential Moveo (low‐fluence scanning) and Standard (fractional stamping) modes. Outcomes were assessed at baseline and at 1, 3, and 6 months after the final session, including Goodman and Baron quantitative scores (GBQGASGS), Antera® 3D imaging device, patient satisfaction, procedural pain, and adverse events. Results GBQGASGS improved by 14.5% at 6 months after the final treatment (19.81 ± 7.31 to 16.94 ± 7.18; p = 0.001), with a 9.7% reduction evident 1 month after the second session ( p = 0.017). Antera® 3D analysis demonstrated improvements in skin texture (12.91 ± 4.25 to 11.38 ± 3.97; p = 0.002) and scar volume (2.54 ± 1.33 to 2.04 ± 1.26; p = 0.001). At 6 months, blinded evaluators reported ≥ 25% improvement in 50% of subjects, while 69% of patients reported ≥ 25% improvement. Adverse events were of low incidence and transient in nature, and no serious complications occurred. Conclusions The 675‐nm laser demonstrated significant and sustained improvements in acne scar metrics in Asian patients with FST III–IV, supporting its role as a pigment‐safe, nonablative option for atrophic acne scars in skin of color. Trial Registration: Thai Clinical Trials Registry: TCTR20250218009.
Nisagornsen et al. (Sun,) studied this question.